Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Yao, Longbiao ^a   Herlea Pana, Oana ^a   Heuser Baker, Janet ^a   Chen, Yitong ^a   Barlic Dicen, Jana ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; FRACTALKINE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CHEMOKINE RECEPTOR;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CELL TYPE; CHOLESTEROL METABOLISM; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; ENERGY EXPENDITURE; ENVIRONMENTAL TEMPERATURE; GLUCOSE TRANSPORT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOCYTE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS FAT; ANIMAL; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CHEMOKINES; HUMANS; INSULIN RESISTANCE; OBESITY; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 84897549119     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/181450     Document Type: Review

References (102)

1. Rosen E. D., Spiegelman B. M., Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006 444 7121 847 853 2-s2.0-33845864967 10.1038/nature05483 (Pubitemid 46024991)
2. Bachelerie F., Ben-Baruch A., Burkhardt A. M., International union of pharmacology. LIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacological Reviews 2014 66 1 1 79
3. Giralt M., Villarroya F., White, brown, beige/brite: different adipose cells for different functions? Endocrinology 2013 154 9 2992 3000 10.1210/en.2013-1403
4. Schulz T. J., Tseng Y., Brown adipose tissue: development, metabolism and beyond. Biochemical Journal 2013 453 2 167 178 10.1042/BJ20130457
5. Chawla A., Nguyen K. D., Goh Y. P. S., Macrophage-mediated inflammation in metabolic disease. Nature Reviews Immunology 2011 11 11 738 749 2-s2.0-80355133234 10.1038/nri3071
6. Sun S., Ji Y., Kersten S., Mechanisms of inflammatory responses in obese adipose tissue. Annual Review of Nutrition 2012 32 1 261 286 10.1146/annurev-nutr-071811-150623
7. Anderson E. K., Gutierrez D. A., Hasty A. H., Adipose tissue recruitment of leukocytes. Current Opinion in Lipidology 2010 21 3 172 177 2-s2.0-77952419815 10.1097/MOL.0b013e3283393867
8. Surmi B. K., Hasty A. H., The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascular Pharmacology 2010 52 1-2 27 36 2-s2.0-76049100165 10.1016/j.vph.2009.12.004
9. Hariri N., Thibault L., High-fat diet-induced obesity in animal models. Nutrition Research Reviews 2010 23 2 270 299 2-s2.0-78650535334 10.1017/S0954422410000168
10. Oh D. Y., Morinaga H., Talukdar S., Bae E. J., Olefsky J. M., Increased macrophage migration into adipose tissue in obese mice. Diabetes 2012 61 2 346 354 2-s2.0-84856533216 10.2337/db11-0860
11. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K.-I., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M., MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. The Journal of Clinical Investigation 2006 116 6 1494 1505 2-s2.0-33745216724 10.1172/JCI26498
12. Weisberg S. P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R. L., Ferrante A. W. Jr., CCR2 modulates inflammatory and metabolic effects of high-fat feeding. The Journal of Clinical Investigation 2006 116 1 115 124 2-s2.0-31044456529 10.1172/JCI24335 (Pubitemid 43121796)
13. Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., Ohtsuka-Kowatari N., Kumagai K., Sakamoto K., Kobayashi M., Yamauchi T., Ueki K., Oishi Y., Nishimura S., Manabe I., Hashimoto H., Ohnishi Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Nagai R., Kadowaki T., Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. The Journal of Biological Chemistry 2006 281 36 26602 26614 2-s2.0-33748750917 10.1074/jbc.M601284200 (Pubitemid 44401869)
14. Inouye K. E., Shi H., Howard J. K., Daly C. H., Lord G. M., Rollins B. J., Flier J. S., Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007 56 9 2242 2250 2-s2.0-34548434020 10.2337/db07-0425 (Pubitemid 47358231)
15. Kirk E. A., Sagawa Z. K., McDonald T. O., O'Brien K. D., Heinecke J. W., Monocyte chemoattractant protein-1 deficiency fails to restrain macrophage infiltration into adipose tissue. Diabetes 2008 57 5 1254 1261 2-s2.0-48449102722 10.2337/db07-1061
16. Neels J. G., Badeanlou L., Hester K. D., Samad F., Keratinocyte-derived chemokine in obesity. Expression, regulation, and role in adipose macrophage infiltration and glucose homeostasis. The Journal of Biological Chemistry 2009 284 31 20692 20698 2-s2.0-68949090345 10.1074/jbc.M109.018556
17. Huber J., Kiefer F. W., Zeyda M., Ludvik B., Silberhumer G. R., Prager G., Zlabinger G. J., Stulnig T. M., CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. Journal of Clinical Endocrinology and Metabolism 2008 93 8 3215 3221 2-s2.0-49249116067 10.1210/jc.2007-2630
18. Kitade H., Sawamoto K., Nagashimada M., CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 2012 61 7 1680 1690 10.2337/db11-1506
19. Kennedy A., Webb C. D., Hill A. A., Loss of CCR5 results in glucose intolerance in diet-induced obese mice. American Journal of Physiology: Endocrinology and Metabolism 2013 305 7 E897 E906 10.1152/ajpendo.00177.2013
20. Guo S., Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms. Journal of Endocrinology 2013 10.1530/JOE-13-0327
21. Eheim A., Medrikova D., Herzig S., Immune cells and metabolic dysfunction. Seminars Immunopathology 2014 36 1 13 25
22. Obstfeld A. E., Sugaru E., Thearle M., Francisco A.-M., Gayet C., Ginsberg H. N., Ables E. V., Ferrante A. W. Jr., C-C Chemokine Receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010 59 4 916 925 2-s2.0-77951146612 10.2337/db09-1403
23. Tamura Y., Sugimoto M., Murayama T., Minami M., Nishikaze Y., Ariyasu H., Akamizu T., Kita T., Yokode M., Arai H., C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. Journal of Atherosclerosis and Thrombosis 2010 17 3 219 228 2-s2.0-77951160365
24. Tamura Y., Sugimoto M., Murayama T., Ueda Y., Kanamori H., Ono K., Ariyasu H., Akamizu T., Kita T., Yokode M., Arai H., Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 12 2195 2201 2-s2.0-57549087753 10.1161/ATVBAHA.108.168633
25. Gutierrez D. A., Kennedy A., Orr J. S., Anderson E. K., Webb C. D., Gerrald W. K., Hasty A. H., Aberrant accumulation of undifferentiated myeloid cells in the adipose tissue of CCR2-deficient mice delays improvements in insulin sensitivity. Diabetes 2012 61 5 1302 1304 2-s2.0-84860558000 10.2337/db12-er05
26. Chavey C., Lazennec G., Lagarrigue S., Clapé C., Iankova I., Teyssier J., Annicotte J.-S., Schmidt J., Mataki C., Yamamoto H., Sanches R., Guma A., Stich V., Vitkova M., Jardin-Watelet B., Renard E., Strieter R., Tuthill A., Hotamisligil G. S., Vidal-Puig A., Zorzano A., Langin D., Fajas L., CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metabolism 2009 9 4 339 349 2-s2.0-63649097100 10.1016/j.cmet.2009.03.002
27. Nara N., Nakayama Y., Okamoto S., Tamura H., Kiyono M., Muraoka M., Tanaka K., Taya C., Shitara H., Ishii R., Yonekawa H., Minokoshi Y., Hara T., Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. The Journal of Biological Chemistry 2007 282 42 30794 30803 2-s2.0-35648947853 10.1074/jbc.M700412200 (Pubitemid 350035195)
28. Lee Y., Morinaga H., Kim J., The Fractalkine/CX3CR1 system regulates b-cell function and insulin secretion. Cell 2013 153 2 413 425 10.1016/j.cell.2013.03.001
29. Bays H. E., Toth P. P., Kris-Etherton P. M., Obesity, adiposity, and dyslipidemia: a consensus statement from the national lipid association. Journal of Clinical Lipidology 2013 7 4 304 383 10.1016/j.jacl.2013.04.001
30. Bays H. E., González-Campoy J. M., Bray G. A., Kitabchi A. E., Bergman D. A., Schorr A. B., Rodbard H. W., Henry R. R., Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Review of Cardiovascular Therapy 2008 6 3 343 368 2-s2.0-41449114649 10.1586/14779072.6.3.343
31. Bays H. E., Adiposopathy: is "sick fat" a cardiovascular disease? Journal of the American College of Cardiology 2011 57 25 2461 2473 2-s2.0-79958814620 10.1016/j.jacc.2011.02.038
32. Libby P., Ridker P. M., Hansson G. K., Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 7347 317 325 2-s2.0-79956319051 10.1038/nature10146
33. Mizuno Y., Jacob R. F., Preston Mason R., Inflammation and the development of atherosclerosis-effects of lipid-lowering therapy. Journal of Atherosclerosis and Thrombosis 2011 18 5 351 358 2-s2.0-79958032424 10.5551/jat.7591
34. Liao J. K., Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. American Journal of Cardiology 2005 96 5, supplement 1 24 33 2-s2.0-23944445364 10.1016/j.amjcard.2005.06.009 (Pubitemid 41207730)
35. Zhou Q., Liao J. K., Pleiotropic effects of statins-basic research and clinical perspectives. Circulation Journal 2010 74 5 818 826 2-s2.0-77951709095 10.1253/circj.CJ-10-0110
36. Daugherty A., Mouse models of atherosclerosis. American Journal of the Medical Sciences 2002 323 1 3 10 2-s2.0-0036080373 (Pubitemid 34650115)
37. Altenburg M., Homeister J., Doherty H., Maeda N., Genetics of atherosclerosis in murine models. Current Drug Targets 2007 8 11 1161 1171 2-s2.0-36949019742 10.2174/138945007782403801 (Pubitemid 350238917)
38. Packard R. R. S., Lichtman A. H., Libby P., Innate and adaptive immunity in atherosclerosis. Seminars in Immunopathology 2009 31 1 5 22 2-s2.0-67749090790 10.1007/s00281-009-0153-8
39. Neiken N. A., Coughlin S. R., Gordon D., Wilcox J. N., Monocyte chemoattractant protein-1 in human atheromatous plaques. The Journal of Clinical Investigation 1991 88 4 1121 1127 2-s2.0-0026075699
40. Rayner K., Van Eersel S., Groot P. H. E., Reape T. J., Localisation of mRNA for JE/MCP-1 and its receptor CCR2 in atherosclerotic lesions of the ApoE knockout mouse. Journal of Vascular Research 2000 37 2 93 102 2-s2.0-0034030730 (Pubitemid 30194175)
41. Krohn R., Raffetseder U., Bot I., Zernecke A., Shagdarsuren E., Liehn E. A., Van Santbrink P. J., Nelson P. J., Biessen E. A., Mertens P. R., Weber C., Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 2007 116 16 1812 1820 2-s2.0-37349018318 10.1161/CIRCULATIONAHA.107.708016 (Pubitemid 350287106)
42. Pattison J. M., Nelson P. J., Huie P., Sibley R. K., Krensky A. M., RANTES chemokine expression in transplant-associated accelerated atherosclerosis. Journal of Heart and Lung Transplantation 1996 15 12 1194 1199 2-s2.0-0030465927 (Pubitemid 26428394)
43. Apostolakis S., Krambovitis E., Vlata Z., Kochiadakis G. E., Baritaki S., Spandidos D. A., CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. Thrombosis Research 2007 121 3 387 395 2-s2.0-37749054645 10.1016/j.thromres.2007.04.005
44. Lucas A. D., Bursill C., Guzik T. J., Sadowski J., Channon K. M., Greaves D. R., Smooth muscle cells in human atherosclerotic plaques express the Fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine Fractalkine (CX3CL1). Circulation 2003 108 20 2498 2504 2-s2.0-0344393600 10.1161/01.CIR.0000097119.57756.EF (Pubitemid 37444412)
45. Gu L., Okada Y., Clinton S. K., Gerard C., Sukhova G. K., Libby P., Rollins B. J., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Molecular Cell 1998 2 2 275 281 2-s2.0-0032134003 (Pubitemid 128373654)
46. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998 394 6696 894 897 2-s2.0-0032572719 10.1038/29788 (Pubitemid 28410911)
47. Lu B., Rutledge B. J., Gu L., Fiorillo J., Lukacs N. W., Kunkel S. L., North R., Gerard C., Rollins B. J., Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. Journal of Experimental Medicine 1998 187 4 601 608 2-s2.0-0032536531 10.1084/jem.187.4.601 (Pubitemid 28093362)
48. McDermott D. H., Yang Q., Kathiresan S., Cupples L. A., Massaro J. M., Keaney J. F. Jr., Larson M. G., Vasan R. S., Hirschhorn J. N., O'Donnell C. J., Murphy P. M., Benjamin E. J., CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005 112 8 1113 1120 2-s2.0-24044448618 10.1161/CIRCULATIONAHA.105.543579 (Pubitemid 41216117)
49. Szalai C., Duba J., Prohászka Z., Kalina Á., Szabó T., Nagy B., Horváth L., Császár A., Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001 158 1 233 239 2-s2.0-0034898394 10.1016/S0021-9150(01)00423-3 (Pubitemid 32735489)
50. Braunersreuther V., Zernecke A., Arnaud C., Liehn E. A., Steffens S., Shagdarsuren E., Bidzhekov K., Burger F., Pelli G., Luckow B., Mach F., Weber C., Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 373 379 2-s2.0-33846404914 10.1161/01.ATV.0000253886.44609.ae (Pubitemid 46143054)
51. Combadière C., Potteaux S., Gao J.-L., Esposito B., Casanova S., Lee E. J., Debré P., Tedgui A., Murphy P. M., Mallat Z., Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003 107 7 1009 1016 2-s2.0-0037465557 10.1161/01.CIR. 0000057548.68243.42 (Pubitemid 36258725)
52. Kuziel W. A., Dawson T. C., Quinones M., Garavito E., Chenaux G., Ahuja S. S., Reddick R. L., Maeda N., CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 2003 167 1 25 32 2-s2.0-0037371464 10.1016/S0021-9150(02)00382-9 (Pubitemid 36255632)
53. Teupser D., Pavlides S., Tan M., Gutierrez-Ramos J.-C., Kolbeck R., Breslow J. L., Major reduction of antherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proceedings of the National Academy of Sciences of the United States of America 2004 101 51 17795 17800 2-s2.0-11144242800 10.1073/pnas.0408096101 (Pubitemid 40051966)
54. Veillard N. R., Kwak B., Pelli G., Mulhaupt F., James R. W., Proudfoot A. E. I., Mach F., Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circulation Research 2004 94 2 253 261 2-s2.0-1042291188 10.1161/01.RES.0000109793.17591.4E (Pubitemid 38197459)
55. Böger C. A., Fischereder M., Deinzer M., Aslanidis C., Schmitz G., Stubanus M., Banas B., Krüger B., Riegger G. A. J., Krämer B. K., RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 2005 183 1 121 129 2-s2.0-26244457957 10.1016/j.atherosclerosis.2005.03.006 (Pubitemid 41416830)
56. Simeoni E., Winkelmann B. R., Hoffmann M. M., Fleury S., Ruiz J., Kappenberger L., März W., Vassalli G., Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. European Heart Journal 2004 25 16 1438 1446 2-s2.0-4043072821 10.1016/j.ehj.2004.05.005 (Pubitemid 39078251)
57. González P., Alvarez R., Batalla A., Reguero J. R., Alvarez V., Astudillo A., Cubero G. I., Cortina A., Coto E., Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes and Immunity 2001 2 4 191 195 2-s2.0-0035380993 10.1038/sj.gene.6363760 (Pubitemid 33676982)
58. McDermott D. H., Halcox J. P. J., Schenke W. H., Waclawiw M. A., Merrell M. N., Epstein N., Quyyumi A. A., Murphy P. M., Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circulation Research 2001 89 5 401 407 2-s2.0-0035980162 (Pubitemid 34132655)
59. McDermott D. H., Fong A. M., Yang Q., Sechler J. M., Cupples L. A., Merrell M. N., Wilson P. W. F., D'Agostino R. B., O'Donnell C. J., Patel D. D., Murphy P. M., Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. The Journal of Clinical Investigation 2003 111 8 1241 1250 2-s2.0-0242515752 10.1172/JCI200316790 (Pubitemid 36519941)
60. Apostolakis S., Amanatidou V., Papadakis E. G., Spandidos D. A., Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis 2009 207 1 8 15 2-s2.0-70350572373 10.1016/j.atherosclerosis.2009.03.044
61. Gugl A., Renner W., Seinost G., Brodmann M., Pabst E., Wascher T. C., Paulweber B., Iglseder B., Pilger E., Two polymorphisms in the fracalkine receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis 2003 166 2 339 343 2-s2.0-0037298503 10.1016/S0021-9150(02) 00362-3 (Pubitemid 36071692)
62. Niessner A., Marculescu R., Kvakan H., Haschemi A., Endler G., Weyand C. M., Maurer G., Mannhalter C., Wojta J., Wagner O., Huber K., Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thrombosis and Haemostasis 2005 94 6 1251 1256 2-s2.0-29244441654 10.1160/TH05-06-0417 (Pubitemid 41823845)
63. Tacke F., Alvarez D., Kaplan T. J., Jakubzick C., Spanbroek R., Llodra J., Garin A., Liu J., Mack M., Van Rooijen N., Lira S. A., Habenicht A. J., Randolph G. J., Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. The Journal of Clinical Investigation 2007 117 1 185 194 2-s2.0-33845989083 10.1172/JCI28549 (Pubitemid 46048465)
64. Combadière C., Potteaux S., Rodero M., Simon T., Pezard A., Esposito B., Merval R., Proudfoot A., Tedgui A., Mallat Z., Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6Chi and Ly6Clo monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008 117 13 1649 1657 2-s2.0-41649100060 10.1161/CIRCULATIONAHA.107.745091 (Pubitemid 351482605)
65. Bazan J. F., Bacon K. B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D. R., Zlotnik A., Schall T. J., A new class of membrane-bound chemokine with a CX3C motif. Nature 1997 385 6617 640 642 2-s2.0-0031036347 10.1038/385640a0 (Pubitemid 27087578)
66. Barlic J., Zhang Y., Murphy P. M., Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNF α -NF B-dependent manner. The Journal of Biological Chemistry 2007 282 26 19167 19176 2-s2.0-34547094842 10.1074/jbc.M701642200 (Pubitemid 47100191)
67. Barlic J., Zhang Y., Foley J. F., Murphy P. M., Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ -dependent pathway. Circulation 2006 114 8 807 819 2-s2.0-33747611168 10.1161/CIRCULATIONAHA.105.602359 (Pubitemid 44268231)
68. Calvayrac O., Rodríguez-Calvo R., Alonso J., Orbe J., Martín-Ventura J. L., Guadall A., Gentile M., Juan-Babot O., Egido J., Beloqui O., Paramo J. A., Rodríguez C., Martínez-González J., CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF- B. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 11 2733 2741 2-s2.0-80054890466 10.1161/ATVBAHA.111.235721
69. Yilmaz A., Lipfert B., Cicha I., Schubert K., Klein M., Raithel D., Daniel W. G., Garlichs C. D., Accumulation of immune cells and high expression of chemokines/chemokine receptors in the upstream shoulder of atherosclerotic carotid plaques. Experimental and Molecular Pathology 2007 82 3 245 255 2-s2.0-34247586138 10.1016/j.yexmp.2006.10.008 (Pubitemid 46686659)
70. Wan W., Lim J. K., Lionakis M. S., Rivollier A., McDermott D. H., Kelsall B. L., Farber J. M., Murphy P. M., Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circulation Research 2011 109 4 374 381 2-s2.0-80051718898 10.1161/CIRCRESAHA.111.242578
71. Manthey H. D., Cochain C., Barnsteiner S., CCR6 selectively promotes monocyte mediated inflammation and atherogenesis in mice. Thrombosis and Haemostasis 2013 110 12 1267 1277 10.1160/TH13-01-0017
72. Imai T., Baba M., Nishimura M., Kakizaki M., Takagi S., Yoshie O., The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. The Journal of Biological Chemistry 1997 272 23 15036 15042 2-s2.0-0030987778 10.1074/jbc.272.23.15036 (Pubitemid 27251781)
73. Greaves D. R., Häkkinen T., Lucas A. D., Liddiard K., Jones E., Quinn C. M., Senaratne J., Green F. R., Tyson K., Boyle J., Shanahan C., Weissberg P. L., Gordon S., Ylä-Hertualla S., Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 6 923 929 2-s2.0-0035715132 (Pubitemid 34168647)
74. Weber C., Meiler S., Döring Y., Koch M., Drechsler M., Megens R. T. A., Rowinska Z., Bidzhekov K., Fecher C., Ribechini E., Van Zandvoort M. A. M. J., Binder C. J., Jelinek I., Hristov M., Boon L., Jung S., Korn T., Lutz M. B., Förster I., Zenke M., Hieronymus T., Junt T., Zernecke A., CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. The Journal of Clinical Investigation 2011 121 7 2898 2910 2-s2.0-79960020852 10.1172/JCI44925
75. Boisvert W. A., Rose D. M., Johnson K. A., Fuentes M. E., Lira S. A., Curtiss L. K., Terkeltaub R. A., Up-regulated expression of the CXCR2 ligand KC/GRO- α in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. American Journal of Pathology 2006 168 4 1385 1395 2-s2.0-33645456200 10.2353/ajpath.2006.040748
76. Boisvert W. A., Santiago R., Curtiss L. K., Terkeltaub R. A., A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor- deficient mice. The Journal of Clinical Investigation 1998 101 2 353 363 2-s2.0-0032518420 (Pubitemid 28067332)
77. Boisvert W. A., Curtiss L. K., Terkeltaub R. A., Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunologic Research 2000 21 2-3 129 137 2-s2.0-0033846028
78. Heller E. A., Liu E., Tager A. M., Yuan Q., Lin A. Y., Ahluwalia N., Jones K., Koehn S. L., Lok V. M., Aikawa E., Moore K. J., Luster A. D., Gerszten R. E., Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006 113 19 2301 2312 2-s2.0-33744981802 10.1161/CIRCULATIONAHA.105.605121 (Pubitemid 43947976)
79. Gao J.-L., Kuhns D. B., Tiffany H. L., McDermott D., Li X., Francke U., Murphy P. M., Structure and functional expression of the human macrophage inflammatory protein 1 α /RANTES receptor. Journal of Experimental Medicine 1993 177 5 1421 1427 2-s2.0-0027479459 (Pubitemid 23117132)
80. Potteaux S., Combadière C., Esposito B., Casanova S., Merval R., Ardouin P., Gao J.-L., Murphy P. M., Tedgui A., Mallat Z., Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lession development and inflammation in mice. Molecular Medicine 2005 11 1-12 16 20 2-s2.0-33646529363 10.2119/2005-00028.Potteaux
81. +T cells. Blood 2001 97 4 1144 1146 2-s2.0-0035865599 10.1182/blood.V97.4.1144 (Pubitemid 32154307)
82. Ebert L. M., Schaerli P., Moser B., Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Molecular Immunology 2005 42 7 799 809 2-s2.0-16844382244 10.1016/j.molimm.2004.06.040 (Pubitemid 40489029)
83. Damås J. K., Smith C., Øie E., Fevang B., Halvorsen B., Wæhre T., Boullier A., Breland U., Yndestad A., Ovchinnikova O., Robertson A.-K. L., Sandberg W. J., Kjekshus J., Taskén K., Frøland S. S., Gullestad L., Hansson G. K., Quehenberger O., Aukrust P., Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 3 614 620 2-s2.0-33847061264 10.1161/01.ATV.0000255581.38523.7c
84. Wan W., Lionakis M. S., Liu Q., Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in apoE-deficient mice. Cardiovascular Research 2013 97 3 580 588 10.1093/cvr/cvs349
85. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S.-I., Kishimoto T., Nagasawa T., The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998 393 6685 591 594 2-s2.0-0032508033 10.1038/31261 (Pubitemid 28319250)
86. Zou Y.-R., Kottman A. H., Kuroda M., Taniuchi I., Littman D. R., Function of the chemokine receptor CXCR4 in heaematopolesis and in cerebellar development. Nature 1998 393 6685 595 599 2-s2.0-0032507962 10.1038/31269 (Pubitemid 28319251)
87. Ma Q., Jones D., Borghesani P. R., Segal R. A., Nagasawa T., Kismimoto T., Bronson R. T., Springer T. A., Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1998 95 16 9448 9453 2-s2.0-0032482926 10.1073/pnas.95.16.9448 (Pubitemid 28506251)
88. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S.-I., Kitamura Y., Yoshida N., Kikutani H., Kishimoto T., Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996 382 6592 635 638 2-s2.0-0029758113 10.1038/382635a0 (Pubitemid 26268957)
89. Bleul C. C., Fuhlbrigge R. C., Casasnovas J. M., Aiuti A., Springer T. A., A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). Journal of Experimental Medicine 1996 184 3 1101 1109 2-s2.0-0029833943 (Pubitemid 26313567)
90. Motabi I. H., DiPersio J. F., Advances in stem cell mobilization. Blood Reviews 2012 26 6 267 278 10.1016/j.blre.2012.09.003
91. Damås J. K., Wæhre T., Yndestad A., Ueland T., Müller F., Eiken H. G., Holm A. M., Halvorsen B., Frøland S. S., Gullestad L., Aukrust P., Stromal cell-derived factor-1 α in unstable angina potential antiinflammatory and matrix-stabilizing effects. Circulation 2002 106 1 36 42 2-s2.0-0036645577 10.1161/01.CIR.0000020001.09990.90 (Pubitemid 34747439)
92. Xu Q., Wang J., He J., Zhou M., Adi J., Webster K. A., Yu H., Impaired CXCR4 expression and cell engraftment of bone marrow-derived cells from aged atherogenic mice. Atherosclerosis 2011 219 1 92 99 2-s2.0-80054982170 10.1016/j.atherosclerosis.2011.07.118
93. Zernecke A., Bot I., Djalali-Talab Y., Shagdarsuren E., Bidzhekov K., Meiler S., Krohn R., Schober A., Sperandio M., Soehnlein O., Bornemann J., Tacke F., Biessen E. A., Weber C., Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circulation Research 2008 102 2 209 217 2-s2.0-41149085145 10.1161/CIRCRESAHA.107.160697 (Pubitemid 351651125)
94. -/- mice during disease regression. The Journal of Clinical Investigation 2011 121 5 2025 2036 2-s2.0-79955503060 10.1172/JCI43802
95. Trogan E., Feig J. E., Dogan S., Rothblat G. H., Angeli V., Tacke F., Randolph G. J., Fisher E. A., Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2006 103 10 3781 3786 2-s2.0-33644852050 10.1073/pnas.0511043103 (Pubitemid 43376632)
96. Rayner K. J., Sheedy F. J., Esau C. C., Hussain F. N., Temel R. E., Parathath S., Van Gils J. M., Rayner A. J., Chang A. N., Suarez Y., Fernandez-Hernando C., Fisher E. A., Moore K. J., Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. The Journal of Clinical Investigation 2011 121 7 2921 2931 2-s2.0-79960015327 10.1172/JCI57275
97. Feig J. E., Pineda-Torra I., Sanson M., Bradley M. N., Vengrenyuk Y., Bogunovic D., Gautier E. L., Rubinstein D., Hong C., Liu J., Wu C., Van Rooijen N., Bhardwaj N., Garabedian M. J., Tontonoz P., Fisher E. A., LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. The Journal of Clinical Investigation 2010 120 12 4415 4424 2-s2.0-78649867645 10.1172/JCI38911
98. Feig J. E., Rong J. X., Shamir R., Sanson M., Vengrenyuk Y., Liu J., Rayner K., Moore K., Garabedian M., Fisher E. A., HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proceedings of the National Academy of Sciences of the United States of America 2011 108 17 7166 7171 2-s2.0-79955552375 10.1073/pnas.1016086108
99. Feig J. E., Parathath S., Rong J. X., Mick S. L., Vengrenyuk Y., Grauer L., Young S. G., Fisher E. A., Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011 123 9 989 998 2-s2.0-79952736069 10.1161/CIRCULATIONAHA.110.984146
100. Yao L., Heuser-Baker J., Herlea-Pana O., Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering. Stem Cells 2012 30 12 2720 2731 10.1002/stem.1256
101. Lieu H. D., Withycombe S. K., Walker Q., Rong J. X., Walzem R. L., Wong J. S., Hamilton R. L., Fisher E. A., Young S. G., Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation 2003 107 9 1315 1321 2-s2.0-0037432295 10.1161/01.CIR.0000054781.50889.0C (Pubitemid 36314417)
102. Raffai R. L., Apolipoprotein E regulation of myeloid cell plasticity in atherosclerosis. Current Opinion in Lipidology 2012 23 5 471 478 10.1097/MOL.0b013e328356f967